Zepbound vs. Retatrutide: Which Crushes Your Fat Fastest? 🔥

Data don't lie. ~5%–28.7% weight-loss ranked. Real results. 💪

Author

Federick Gonzalez
March 29, 2026

Hey man,

Picture this...

You're at the doctor's office...

holding a printout of weight-loss drugs...

feeling like you're trying to decode nuclear launch codes. 🚀

"Which one actually WORKS?"

Your doc shrugs: "They're all good."

But "good" doesn't cut it when you need GREAT.

Time for the no-BS cage match. 🤼 

The Heavyweight Champion: Retatrutide's Triple Threat

Meet the Mike Tyson (in his prime)... of fat loss... 🥊

Retatrutide hits THREE receptors: GLP-1, GIP, AND glucagon. [1][11]

Phase 3 results?

28.7% body weight GONE in 68 weeks. [11]

That's over 71 pounds... vaporized. 💨

Compare that to:

• Ozempic: ~5-10% (the grandfather getting lapped)

• Wegovy 2.4mg: 14.9% clinical / ~20% real-world [2][3]

• Zepbound: 25.5% (solid, but still second place) [10]

The Dark Horse: CagriSema's Stealth Attack

While everyone's watching the main event...

CagriSema sneaks in with a nasty one-two punch:

✊ Semaglutide (the GLP-1 hammer)

✊ Cagrilintide (the amylin uppercut)

REDEFINE 4 results: 23.0% loss at 84 weeks (vs 25.5% for Zepbound) [10]

PLUS... REDEFINE 1 data shows it drops your blood pressure like a bad habit. [6]

with ~40% of patients decreasing or stopping...

their blood pressure medication entirely.

• Systolic BP: -10.9 mmHg

• Diastolic BP: -5.4 mmHg

Your heart gets younger while your gut gets smaller.

Head-to-Head Smackdown Results

Based on the latest trials and real-world data:

🥇 GOLD: Retatrutide (28.7%) [11]

  • Triple-receptor assault

  • Fastest fat melt

  • Phase 3 trials show 71+ lbs lost

🥈 SILVER: Zepbound (25.5%) [10]

  • Beat CagriSema in head-to-head trial

  • Already FDA approved

  • SURMOUNT trials show maintenance magic [4][7]

🥉 BRONZE: CagriSema (23.0%) [10]

  • Dual mechanism mastery

  • BP bonus benefits

  • FDA approval expected 2026 Q4

The 'Good-But-Not-Great' Trap:

Wegovy HD 7.2mg: 20.7% (clinical) / up to 20% (real-world with app on 2.4 mg) [9][3]

  • Brand new high-dose FDA approval

  • Weekly convenience

  • Good safety profile

Ozempic: ~5-10% at (1.0 - 2.0 mg) doses

  • The grandfather getting lapped

  • Better for diabetes than weight loss

  • Why settle for less?

Speaking of settling for less...

What would you do with an instant $500–$5K credit line?

Even Homer knows the power of credit…

Maybe fund your next health upgrade — fresh gym gear, premium supplements, or even that high-end telehealth consult with a top endocrinologist?

Today's sponsor... Capital One.

Affiliate Disclosure: I may earn a small commission if you apply and get approved through the link above, at no extra cost to you. This helps keep Mens Health Secrets free, valuable, and keeps the lights on. 💡

Table For Nerds: 👨‍⚕️ 🤓 

Here's a quick comparison so you know—what to expect from each weight-loss drug:

This is an illustrative case study based on typical patient pathways:

Meet Frank, 47, Former Air Force Special Operations Pararescue (PJs) Operator...

268 pounds of frustration...

Started Ozempic... lost 38 pounds in 6 months.

Then plateaued HARD.

Switched to Zepbound...

Dropped another 42 pounds in 8 months.

Total: 80 pounds gone. 30% of his body weight.

"I feel like I got my operational edge back."

Now he's eyeing Retatrutide for the final push. 💪

The Science Behind The Slaughter

Here's why triple-agonists dominate: [1][8]

GLP-1: Slows stomach emptying

GIP: Enhances insulin, redirects toxic fat away from organs

Glucagon: Cranks up calorie burn

It's like having SEAL Team SIX, Army Delta Force, AND British SAS...

all attacking your fat cells simultaneously. 🎯

One receptor? That's Ozempic playing checkers.

Three receptors? That's Retatrutide playing 3D chess.

Your Personal Battle Plan

The "best" drug depends on YOUR situation:

Choose Retatrutide if: 

✓ You want the most fat annihilation

✓ You can wait for FDA approval (likely 2027-2028)

✓ You're comfortable with newer drugs

✓ You prepare with your doctor to track transient heart rate increases—during the dose escalation phase

Choose CagriSema if: [5]

✓ You have high blood pressure

✓ You want proven dual-action power

✓ You can access trials or wait for 2026 Q4

Choose Zepbound if: 

✓ You want proven results NOW

✓ You need FDA-approved options

✓ You want strong maintenance data

Choose Wegovy if: 

✓ You're starting your journey

✓ You want established safety data

✓ You use digital support apps

The Maintenance Game Nobody Talks About

Here's the dirty secret...

Losing weight? That's the easy part.

KEEPING it off?

That's where men separate from the boys.

SURMOUNT-4 data shows: [7]

• Continued Zepbound = maintained 25.3% loss

• Stopped treatment = regained 14% in 1 year

Translation: These aren't magic bullets.

They're tools that need commitment.

Your Next Mission

Stop playing drug roulette.

Don’t gamble with your health…

Get strategic.

Here's your action plan:

  1. Calculate your target: What % loss gets you to goal?

  2. Check your timeline: Can you wait for newer options?

  3. Consider comorbidities: BP issues? Diabetes? Factor them in.

  4. Find the right doc: Not all prescribe all options.

Want my personal "Drug Selection Decision Tree"?

Reply "CAGE MATCH" and I'll send:

• Side-by-side comparison chart

• Questions to grill your doctor

• Access pathways for each drug

• Real patient success stories

Don't just lose weight.

Lose it smart and keep it off.

To your transformation,

Mens Health Secrets 
–Live Past 100

EMAIL SERIES SPONSOR:

Affiliate Disclosure: I may earn a small commission if you apply and get approved through this link, at no extra cost to you. This helps support the newsletter.

P.S. Next email wraps up this weight-loss drug peptide series. We'll go over your muscle‑first plan, and doc‑ready checklist. 🚀

P.P.S. Always consult with your doctor or specialist before—starting any weight-loss medication. This newsletter is for education and entertainment only... Edutainment. We assume no liability.

P.P.P.S. >>> Go here to subscribe to our Mens Health Secrets YouTube Channel if you haven't yet…. leave a comment… and level up your Mens Health knowledge to live longer.

P.P.P.P.S. New Skool group: FREE. FREE. FREE... for life through Q2. Reply "TRIBE." Your Mens Health Secrets community is waiting.

Medical References:

[1] Jastreboff, A. M., Kaplan, L. M., & Hartman, M. L. (2023). Triple-hormone-receptor agonist retatrutide for obesity - A phase 2 trial. New England Journal of Medicine, 389(6), 514-526. https://doi.org/10.1056/NEJMoa2301972

[2] Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183

[3] Toliver, J. C., Divino, V., Ng, C. D., & Wang, J. (2025). Real-world weight loss among patients initiating semaglutide 2.4 mg and enrolled in WeGoTogether, a digital self-support application. Advances in Therapy, 42(10), 5010-5022. https://doi.org/10.1007/s12325-025-03325-1

[4] Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., ... & SURMOUNT-1 Study Group. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038

[5] Garvey, W. T., & REDEFINE 1 Study Group. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine, 393(7), 635-647. https://doi.org/10.1056/NEJMoa2502081

[6] Verma, S., Böttcher, M., Dicker, D., Rubino, D., Sbraccia, P., ... & Sørrig, R. (2026). CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE 1. Hypertension, 83(2), e26055. https://doi.org/10.1161/HYPERTENSIONAHA.125.26055

[7] Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., ... & SURMOUNT-4 Study Group. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38-48. https://doi.org/10.1001/jama.2023.24945

[8] Salem V, Izzi-Engbeaya C, Coello C, Thomas DB, Chambers ES, Comninos AN, Buckley A, Win Z, Al-Nahhas A, Rabiner EA, Gunn RN, Budge H, Symonds ME, Bloom SR, Tan TM, Dhillo WS. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2016 Jan;18(1):72-81. https://doi.org/10.1111/dom.12585. Epub 2015 Nov 20. PMID: 26434748; PMCID: PMC4710848.

[9] Wharton, S., Ferré, P., Hainer, J., Kaske, M., Kaku, K., Lingvay, I., & Greenway, W. T. (2025). Once-weekly subcutaneous semaglutide 7.2 mg in adults with obesity (STEP UP): A randomised, double-blind, placebo-controlled and active-controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 13(11), 949-963. https://doi.org/10.1016/S2213-8587(25)00226-8

[10] Novo Nordisk A/S. (2026, February 23). CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved [Press release]. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501

[11] Eli Lilly and Company. (2025, December 11). Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial [Press release]. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average